Yahoo
    Nasdaq - Delayed Quote USD

    Driehaus Small Cap Growth Investor (DVSMX)

    27.70 -0.69 (-2.43%)
    At close: 6:59:28 PM EDT
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for DVSMX
    • Previous Close 28.39
    • YTD Return 6.82%
    • Expense Ratio 0.93%
    • Category Small Growth
    • Last Cap Gain 15.00
    • Morningstar Rating
    • Morningstar Risk Rating High
    • Net Assets 1.57B
    • Beta (5Y Monthly) 1.50
    • Yield 0.20%
    • 5y Average Return --
    • Holdings Turnover 152.00%
    • Last Dividend 0.06
    • Inception Date Aug 21, 2017

    The fund uses a growth style of investment in equity securities, including common stocks and other equity securities of issuers. Under normal market conditions, it invests at least 80% of its net assets (plus the amount of borrowings for investment purposes) in the equity securities of U.S. small-capitalization ("small cap") companies. The fund may invest in companies with limited or no operating histories.

    Driehaus

    Fund Family

    Small Growth

    Fund Category

    1.57B

    Net Assets

    2017-08-21

    Inception Date

    More about Driehaus Small Cap Growth Investor

    Performance Overview

    View More

    Trailing returns as of 10/28/2026. Category is Small Growth.

    YTD Return

    DVSMX
    6.82%
    Category
    12.40%

    1-Year Return

    DVSMX
    12.58%
    Category
    55.69%

    3-Year Return

    DVSMX
    20.13%
    Category
    19.34%

    5-Year Return

    DVSMX
    5.53%
    Category
    20.72%

    People Also Watch

    DNSMX Driehaus Small Cap Growth Institutional
    28.31 -2.45%
    DMCRX Driehaus Micro Cap Growth
    17.88 -2.51%
    LMIYX Lord Abbett Micro Cap Growth I
    27.26 -1.87%
    LFMGX Lord Abbett Micro Cap Growth F
    27.26 -1.87%
    LAMGX Lord Abbett Micro Cap Growth A
    21.92 -1.88%

    Related Mutual Fund News

    View More
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire 3h ago
    They Called This Stock a Winner in the AI Coding Boom. A Year Later, It’s Up 94%.

    They Called This Stock a Winner in the AI Coding Boom. A Year Later, It’s Up 94%.
    24/7 Wall St. 6h ago
    1 small-cap stock with competitive advantages and 2 facing challenges

    1 small-cap stock with competitive advantages and 2 facing challenges
    StockStory 7h ago
    Illumina Sinks 13% on Light Q3 Revenue Despite EPS Beat and Raised Guidance

    Illumina Sinks 13% on Light Q3 Revenue Despite EPS Beat and Raised Guidance
    TIKR 9h ago
    Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

    Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
    Business Wire 1d ago
    Can GitLab Stock Get Back To Where It Was?

    Can GitLab Stock Get Back To Where It Was?
    Trefis 1d ago
    Long Oligo Pool Synthesis for Capture Global Market Report 2026 | Capitalize on $3.31B by 2030 as Twist Bioscience, Agilent, Eurofins and BGI Scale AI-Driven Precision Oncology

    Long Oligo Pool Synthesis for Capture Global Market Report 2026 | Capitalize on $3.31B by 2030 as Twist Bioscience, Agilent, Eurofins and BGI Scale AI-Driven Precision Oncology
    GlobeNewswire 1d ago
    Robust Demand Across BioPharma and NGS Applications Elevates Twist Bioscience Corp.’s (TWST) Growth Profile

    Robust Demand Across BioPharma and NGS Applications Elevates Twist Bioscience Corp.’s (TWST) Growth Profile
    Insider Monkey 1d ago
    Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia

    Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
    GlobeNewswire 1d ago
    Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
    Zacks 1d ago
    Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

    Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
    GlobeNewswire 1d ago
    View More

    Top Mutual Funds

    BIVSX Invenomic Super Institutional
    20.35 +4.79%
    CNPIX Consumer Staples UltraSector ProFund Inv
    84.08 +2.22%
    CNPSX Consumer Staples UltraSector ProFund Svc
    72.29 +2.22%
    FTVCX FullerThaler Behav Md-Cp Val C
    35.14 +1.80%
    FSENX Fidelity Select Energy Portfolio
    99.69 +1.79%
    FTVAX FullerThaler Behav Md-Cp Val A
    35.42 +1.78%
    RYAHX Rydex Mid-Cap 1.5x Strategy A
    159.44 +1.77%
    RYMDX Rydex Mid-Cap 1.5x Strategy H
    160.18 +1.77%
    PGRQX PGIM Global Real Estate R6
    21.60 +1.74%
    PURZX PGIM Global Real Estate Z
    21.61 +1.74%
    TVSVX Third Avenue Small Cap Value Investor
    24.29 0.00%
    PURGX PGIM Global Real Estate R4
    21.57 +1.70%
    PURAX PGIM Global Real Estate A
    21.40 +1.61%
    FPHAX Fidelity Select Pharmaceuticals Port
    38.14 +1.49%
    OFVIX O'Shaughnessy Market Leaders Value I
    22.03 0.00%
    LSHCX Kinetics Spin-Off and Corp Rest Adv C
    23.68 +1.41%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: